Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Muscle & Nerve. Supplement
|
January 1, 1997
Injection techniques for botulinum toxin using electromyography and electrical stimulation
C F O'Brien
Advances in Neurology
|
May 12, 2001
Chemodenervation with botulinum toxin for spasticity and dystonia. The effects on gait
C F O'Brien
Seminars in Neurology
|
September 1, 1995
Involuntary movement disorders following lightning and electrical injuries
C F O'Brien
Neurology
|
June 20, 1998
Extending levodopa action: COMT inhibition
P Martínez-Martín, C F O'Brien
Archives of Neurology
|
September 1, 1991
N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease
J T Greenamyre, C F O'Brien
Muscle & Nerve. Supplement
|
January 1, 1997
A clinical overview of treatment decisions in the management of spasticity
M E Gormley, C F O'Brien, S A Yablon
Drugs & Aging
|
November 1, 1996
Spasticity after stroke. Epidemiology and optimal treatment
C F O'Brien, L C Seeberger, D B Smith
Neuroscience Letters
|
October 28, 1991
Heterogeneous dopamine receptor changes in early and late Huntington's disease
E K Richfield, C F O'Brien, T Eskin, et al.
Neurorehabilitation and Neural Repair
|
August 31, 2001
The estimated cost of managing focal spasticity: a physician practice patterns survey
P W Radensky, J W Archer, S F Dournaux, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 26, 1997
BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study)
D D Truong, P A Cullis, C F O'Brien, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Muscle & Nerve. Supplement
|
January 1, 1997
Injection techniques for botulinum toxin using electromyography and electrical stimulation
C F O'Brien
Advances in Neurology
|
May 12, 2001
Chemodenervation with botulinum toxin for spasticity and dystonia. The effects on gait
C F O'Brien
Seminars in Neurology
|
September 1, 1995
Involuntary movement disorders following lightning and electrical injuries
C F O'Brien
Neurology
|
June 20, 1998
Extending levodopa action: COMT inhibition
P Martínez-Martín, C F O'Brien
Archives of Neurology
|
September 1, 1991
N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease
J T Greenamyre, C F O'Brien
Muscle & Nerve. Supplement
|
January 1, 1997
A clinical overview of treatment decisions in the management of spasticity
M E Gormley, C F O'Brien, S A Yablon
Drugs & Aging
|
November 1, 1996
Spasticity after stroke. Epidemiology and optimal treatment
C F O'Brien, L C Seeberger, D B Smith
Neuroscience Letters
|
October 28, 1991
Heterogeneous dopamine receptor changes in early and late Huntington's disease
E K Richfield, C F O'Brien, T Eskin, et al.
Neurorehabilitation and Neural Repair
|
August 31, 2001
The estimated cost of managing focal spasticity: a physician practice patterns survey
P W Radensky, J W Archer, S F Dournaux, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 26, 1997
BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study)
D D Truong, P A Cullis, C F O'Brien, et al.
Page
of 2